Phase 2 Migraine Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adolescents who are between 14 and 17 years old at the time of screening
- People diagnosed with Chronic Migraine, meaning headaches occurring on 15 or more days per month for more than 3 months, with at least 8 of those days having migraine features
- People who have already tried at least two treatments that did not work well or caused side effects — these may include certain antidepressants, magnesium, epilepsy medications such as topiramate, or non-medication-based therapies
- Females who have started their menstrual periods must have a negative pregnancy test at screening
- People who are willing to attend psychology and physiotherapy sessions as part of the trial
Who may not be able to join:
- People whose personal circumstances or medical situation, in the opinion of the trial investigator, would make it difficult to complete the study
- People with a history of headaches caused by concussion, or a type of daily headache that started suddenly and never went away
- People diagnosed with headaches caused by overuse of pain or migraine medication
- People with heart, kidney, or liver disease (as assessed by the trial site)
- People with a condition called Complex Regional Pain Syndrome Type II
- People with an abnormal heart tracing (ECG) result at the start of the trial, as determined by the investigator
- People currently taking opioids, antipsychotics, antimanic medications, barbiturates, benzodiazepines, muscle relaxants, sedatives, or tramadol
- People with developmental conditions including autism, cerebral palsy, or intellectual disability
- People with a personal or family history of schizophrenia or psychotic disorders
- People who are pregnant, breastfeeding, or planning to become pregnant during the study or within three months of finishing the trial treatment
- People who are unable to commit to using contraception, avoiding recreational cannabis, and avoiding driving throughout the study period
- People with a known allergy to cannabinoids or to palm or coconut oil
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lauren E Kelly, PhD, University of Manitoba
Phone: 2042723149
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cannabis-related adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.